Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serine β-lactamases are a subclass of serine proteases that hydrolyze the β-lactam ring of beta-lactam antibiotics, conferring antibiotic resistance in bacteria. They utilize a serine residue in their active site for catalysis. They are classified into Ambler classes A, C, and D, based on sequence homology. The catalytic mechanism involves acylation and deacylation reactions. Inhibitors of serine β-lactamases are being developed to restore the efficacy of beta-lactam antibiotics. Variants of these enzymes, such as ESBLs and carbapenemases, are clinically relevant due to their expanded substrate range.
Acylation/deacylation via nucleophilic attack by serine on beta-lactam ring.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serine protease (serine β-lactamase).